Poolbeg Pharma Gains FDA Orphan Drug Status for Groundbreaking CRS Prevention Treatment

Highlights

Team Kalkine | 27 May 2025

Poolbeg Pharma Raises £4.87M to Advance Clinical Trials, Extends Cash Runway to 2027

Highlights

Team Kalkine | 23 May 2025

IXICO Releases First-Half Results, On Track to Exceed 2025 Expectations

Highlights

Team Kalkine | 20 May 2025

Poolbeg Pharma Launches £4.1 Million Fundraise to Advance Cancer and Obesity Treatments

Highlights

Team Kalkine | 20 May 2025

Arecor (AIM: AREC) and Skye Bioscience Collaborate on Enhanced Formulation of Obesity Drug Candidate

Arecor Therapeutics plc (AIM: AREC)has announced a new collaboration with US-based Skye Bioscience (Nasdaq: SKYE) to develop a higher concentration formulation of nimacimab, a monoclonal antibody currently under investigation for the treatment of obesity and related metabolic conditions.

Team Kalkine | 19 May 2025

Genflow Biosciences Advances SIRT6 Gene Therapy Patent in Japan

Highlights

Team Kalkine | 15 May 2025

GSK Acquires Promising Liver Disease Drug Efimosfermin in $2 Billion Deal to Tackle Global Hepatology Crisis

In a strategic move to bolster its liver disease portfolio, GSK plc (LSE:GSK) has announced the acquisition of efimosfermin alfa, a promising investigational treatment for steatotic liver disease (SLD), from Boston Pharmaceuticals. The deal, valued at $2 billion, includes an upfront payment of $1.2 …

Team Kalkine | 14 May 2025

Healthcare

Poolbeg Pharma Gains FDA Orphan Drug Status for Groundbreaking CRS Prevention Treatment

Poolbeg Pharma Raises £4.87M to Advance Clinical Trials, Extends Cash Runway to 2027

IXICO Releases First-Half Results, On Track to Exceed 2025 Expectations

Poolbeg Pharma Launches £4.1 Million Fundraise to Advance Cancer and Obesity Treatments

Arecor (AIM: AREC) and Skye Bioscience Collaborate on Enhanced Formulation of Obesity Drug Candidate

Genflow Biosciences Advances SIRT6 Gene Therapy Patent in Japan

GSK Acquires Promising Liver Disease Drug Efimosfermin in $2 Billion Deal to Tackle Global Hepatology Crisis

GSK Delivers Positive Start to 2025 with Surge in Specialty Medicines and Robust Pipeline Momentum

Smith+Nephew Delivers Q1 Revenue Growth, Maintains 2025 Outlook Amid Global Headwinds

AstraZeneca Shares Dip Despite Increase in Earnings and Oncology Surge

Latest News

Is LSE:IOF One Of The Strongest Commodity-Linked Growth Stories On AIM?

Can Pantheon Resources Deliver on Its Alaska Oil Potential?

Is Altona Rare Earths a Hidden Rare Earth Opportunity?

Are UK Industrial Stocks Like Castings Undervalued?

How Does Market Volatility Affect CMCX Revenue?

Can Nanoco Survive as a Microcap Technology Stock?